Mayo Clinic Laboratory and Pathology Research Roundup: April 23

By Sarah Jarvis • April 23, 2024

Share this:

The research roundup provides an overview of the past week’s research from Mayo Clinic Laboratories consultants, including featured abstracts and a complete list of published studies and reviews.

Featured Abstract

Evaluation of tumor response to immune checkpoint inhibitors by a 3D immunotumoroid model.

Only 20 percent of renal and bladder cancer patients will show a significant response to immune checkpoint inhibitor (ICI) therapy, and no test currently available accurately predicts ICI response. We developed an "immunotumoroid" cell model system that recapitulates the tumor, its microenvironment, and necessary immune system components in patient-derived spheroids to enable ex vivo assessment of tumor response to ICI therapy.

Read more.

Published to PubMed This Week

• The reply.
  The American Journal of Medicine
• Outpatient treatment with concomitant vaccine-boosted convalescent plasma for patients with immunosuppression and COVID-19.
  mBio
• Single nucleotide polymorphism (SNP) chromosomal microarray as a diagnostic tool for mucinous tubular and spindle cell carcinoma: A validation study.
  Human Pathology
• A call for universal definition of myocardial infarction after cardiac surgery.
  European Journal of Cardio-Thoracic Surgery
• Imaging features of perinephric myxoid pseudotumors of fat.
  Abdominal Radiology
• A 3-step method for preparing cryopreserved samples of apheresis products for post-thaw analysis yields a higher percentage of viable cells.
  Transfusion
• Frontal hypometabolism in the diagnosis of progressive supranuclear palsy clinical variants.
  Journal of Neurology

Sarah Jarvis

Sarah Jarvis is a Senior Marketing Specialist at Mayo Clinic Laboratories. She supports marketing strategies for paid media.